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a Vehicle for Cost-Effectiveness AnalysisAll health care systems that are collectively funded through
taxation or insurance make funding and coverage decisions
considering value for money. Over the past 25 years or so, more
systems have started to use formal cost-effectiveness analysis
(CEA) to inform decisions, particularly those relating to the
funding of new prescription pharmaceuticals. Inevitably and
correctly, decision makers augment CEA with their own judg-
ments about the reliability and relevance of evidence and the
consequences of interventions, which may be poorly reﬂected in
CEA outcomes. One important contribution of the greater use of
CEA, however, has been to highlight some key principles that
should be used in making resource allocation decisions. CEA
undertaken alongside randomized controlled trials (RCTs) will
often be inconsistent with these principles [1].
RCTs provide highly valuable evidence to support decision
making. This is particularly true in the case of relative treatment
effects, the estimation of which ideally requires randomization to
reduce the risk of selection bias. Trials can provide other valuable
information for CEA including data relating to the disease under
current treatment(s), as well as resource use and health-related
quality-of-life data. ISPOR’s updated task force report on CEA
alongside trials provides important guidance on how economic
considerations should shape the design of the trials and the
methods of data collection [2]. But a trial-based CEA goes beyond
the use of evidence collected in RCTs in CEA. Such a study relates
only to the population included in the trial, just includes the clinical
and resource use evidence from that RCT, compares only those
interventions to which patients were randomized, and has a time
horizon deﬁned by the trial’s follow-up period. How often are these
characteristics consistent with the key criteria for evidence-based
decision making?
A number of important principles exist in undertaking CEA to
support decisions. When assessing the relevance of trial-based
CEA, four seem important to emphasize. The ﬁrst is that CEA
should relate to the population that will actually receive the
interventions being evaluated. The task force provides a helpful
summary of the challenges to the external validity of trials and
some methods to address these. Often, concerns about external
validity relate less to a trial’s estimates of relative effectiveness
and more to absolute beneﬁts, which also drive cost-
effectiveness. This can be dealt with using modeling. The relative
treatment effect is taken from the trial (e.g., a hazard ratio) and is
applied to a baseline measure. The latter should relate to the
population of interest and can often come from locally available
nonrandomized data because no treatment effects are being
estimated. This use of modeling and multiple sources of evidence
are also helpful in guiding decisions for subpopulations in whomial support: The author has no other ﬁnancial relaheterogeneity in baseline risks can drive important differences in
cost-effectiveness. There are good examples in coronary stents
[3] and treatments for acute coronary syndrome [4].
A second key principle is that the time horizon of the CEA
should reﬂect the period over which the costs and beneﬁts of the
options being evaluated can differ. The task force is clear that
follow-up periods in trials are often shorter than the necessary
time horizons for CEAs and that extrapolation will generally need
to be undertaken using modeling, sometimes using data other
than from the trial.
The third principle that needs to be reﬂected in a CEA is to
include all options (or comparators against a new interven-
tion). For most diseases, there is an extensive range of
interventions available. Furthermore, sometimes manage-
ment is in the form of strategies such as treatment sequences
or the use of starting or stopping rules for therapies. The
designs of RCTs rarely reﬂect the full range of management
options available, but CEA usually seeks to inform decisions
such as the best way of treating patients, the most appropriate
diagnostic strategy, or whether a new technology is better
than existing alternatives. Undertaking a CEA based only on
the options compared in a single RCT, rather than the full
range of alternatives, risks generating misleading conclusions
to guide decisions. Trial-based CEA may be suitable when, for
example, a new treatment is being evaluated on top of usual
care, which is represented in the trial’s control group. More
generally, however, bringing evidence together from a number
of clinical studies is necessary to consider all alternatives, and
this will need a modeling framework.
The ﬁnal principle is one CEA holds in common with
evidence-based medicine more generally: the need to incorpo-
rate all relevant evidence. Trial-based CEA is invariably, how-
ever, based on the evidence generated by one RCT, so any other
evidence on treatment effects, outcomes, and resources is
effectively ignored. In guiding decision makers about whether
to fund a new technology, CEA would need to consider, for
example, all RCTs (and perhaps observational studies) generat-
ing estimates of treatment effect for the new intervention and
all comparators. This is why systematic review and evidence
synthesis are such important components of health technology
assessment [5]. The combination of the need to include all
alternatives and relevant evidence in CEA is a major factor
behind the development of network meta-analysis to estimate
the relative effectiveness of treatments not directly compared in
RCTs [6]. To bring together the full range of evidence on all
parameters bearing on cost-effectiveness needs modeling, and
good examples abound [7,8].tionships to disclose.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 4 1 – 1 4 2142The importance of RCTs in generating evidence is beyond doubt,
but what is the role of trial-based CEA? In principle, such analyses
are consistent with the needs of decision making if they include the
full range of alternative options, relate to the population for which
the decision is being taken, represent the sole source of relevant
evidence, and have a follow-up consistent with the appropriate
time horizon. In practice, some trial-based CEAs exist that satisfy
these criteria even if they do so more qualitatively than quantita-
tively. It remains the case, however, that analysts should design
their studies on the basis of principles of evidence-based decision
making rather than the availability of data from a particular trial,
and this will generally lead them to conduct CEA using systematic
review, evidence synthesis, and decision analytic modeling.
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